New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust… EP News Bureau Nov 19, 2021 Six months' follow-up of prevention trial showed 83 per cent reduced risk of symptomatic COVID-19, with no severe disease or…
